imipramine has been researched along with Panic Disorder in 143 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and tolerability of sertraline and imipramine in patients with comorbid panic disorder and major depressive disorder." | 9.10 | Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. ( Arató, M; Austin, C; Lepola, U; Zhu, Y, 2003) |
| "Pretreatment with imipramine, buspirone, or placebo was compared in 40 patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria for panic disorder and in patients who were discontinuing long-term benzodiazepine use." | 9.10 | Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy. ( García-España, F; Greenblatt, DJ; Mandos, LA; Rickels, K; Rynn, M; Schweizer, E, 2003) |
| "The study explored whether there is differential efficacy for patients with panic disorder treated with sertraline initially (primary group) versus those switched (transfer group) after intolerance or nonresponse to imipramine in the context of the open 24-week treatment phase of a long-term maintenance/discontinuation study." | 9.10 | Sertraline in panic disorder: initial treatment versus switch strategy. ( Mavissakalian, MR, 2003) |
| "In a recent study, the authors suggested that tachycardia, dry mouth, and sweating continued to burden patients with panic disorder with agoraphobia who have shown marked and stable response to 6 months of imipramine treatment at the fixed, weight-adjusted dose of 2." | 9.10 | Specific side effects of long-term imipramine management of panic disorder. ( Guo, S; Mavissakalian, M; Perel, J, 2002) |
| "It has been suggested that maintenance treatment of patients who have remitted panic disorder with agoraphobia beyond the six months of acute phase imipramine treatment may decrease the risk of relapse." | 9.10 | Duration of imipramine therapy and relapse in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 2002) |
| " The aim of the present study was to assess the 12-month cumulative risk of relapse specifically due to discontinuation of imipramine and to test the hypothesis that maintenance treatment with imipramine protects patients with panic disorder and agoraphobia from such reversals." | 9.09 | Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 1999) |
| "Our data suggest the comparable efficacy of alprazolam and imipramine in the short-term treatment of older adults with panic disorder." | 9.09 | Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. ( Sheikh, JI; Swales, PJ, 1999) |
| "In a recent study, the authors gauged the net effectiveness of imipramine to be 53%; that is, of 110 patients having panic disorder with agoraphobia who started a course of imipramine at a fixed, targeted, weight-adjusted dose of 2." | 9.09 | The side effects burden of extended imipramine treatment of panic disorder. ( Mavissakalian, MR; Perel, JM, 2000) |
| "The results from our 1 year placebo-controlled maintenance/discontinuation study in remitted panic disorder with agoraphobia patients confirmed the significant prophylactic effectiveness of imipramine maintenance treatment but suggested that this may be necessary in only 37% of the patients who relapse following discontinuation of 6 months acute imipramine treatment." | 9.09 | 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 2001) |
| "The aim of this study was to characterize the specific effects of imipramine in the treatment of panic disorder with agoraphobia and to delineate dose-response and possibly plasma level-response relationships." | 9.08 | Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. ( Mavissakalian, MR; Perel, JM, 1995) |
| "Cerebrospinal fluid (CSF) gamma-aminobutyric acid (GABA) levels were measured in 11 patients with panic disorder (PD) prior to and following 7 months of treatment with alprazolam or imipramine and in six neurological control patients." | 9.08 | Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. ( Halonen, T; Jolkkonen, J; Lepola, U; Riekkinen, P; Rimón, R, 1995) |
| " This study investigated the proposition that individual panic symptoms may also differ in their specific responsiveness to treatment in 63 patients with panic disorder with agoraphobia who had completed an 8-week placebo-controlled dose-ranging study with imipramine." | 9.08 | Phenomenology of panic attacks: responsiveness of individual symptoms to imipramine. ( Mavissakalian, MR, 1996) |
| "This report is a descriptive summary of the relationship between response and plasma tricyclic concentrations found in our previously reported dose-ranging study of imipramine (IMI) in panic disorder (Mavissakalian & Perel 1995)." | 9.08 | The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder. ( Mavissakalian, MR; Perel, JM, 1996) |
| "This study compared the efficacy, tolerability, and safety of fluvoxamine, imipramine, and placebo in the treatment of panic disorder with or without agoraphobia." | 9.08 | A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. ( Bakish, D; Charbonneau, Y; Filteau, MJ; Fraser, G; Hooper, CL; Raine, D; Thibaudeau, C; West, DL, 1996) |
| "Fluvoxamine and imipramine were compared to placebo in an 8-week doubleblind randomized multicentre trial comprising of 148 outpatients between 19 and 57 years of age (mean: 35) with a DSM-III-R diagnosis of Panic Disorder." | 9.08 | Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. ( Amin, M; Bakish, D; Nair, NP; Saxena, B; Schwartz, G; West, TE, 1996) |
| "This study examines clinical predictors of outcome for patients with panic disorder and depression in a 16 week, placebo-controlled trial of alprazolam and imipramine (n = 126)." | 9.07 | Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. ( Deltito, JA; Keller, MB; Leon, A; Otto, MW; Pollack, MH; Rosenbaum, JF; Sachs, GS; Shear, MK, 1994) |
| "This article reports the effects of imipramine on heart rate and blood pressure in panic disorder patients who participated in an 8-week double-blind dosage response treatment protocol." | 9.07 | Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm. ( de Groot, CM; Mavissakalian, MR, 1994) |
| "Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment." | 9.07 | Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. ( Lepola, UM; Riekkinen, PJ; Rimón, RH, 1993) |
| "A double-blind, placebo-controlled trial was undertaken to compare the effects of imipramine and clomipramine in the treatment of panic disorder with or without agoraphobia." | 9.07 | Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. ( Eriksson, E; Modigh, K; Westberg, P, 1992) |
| "The reactivity of 40 panic disorder patients on mental arithmetic, cold pressor, and 5% CO2 inhalation stressors was tested before and after 8 weeks of treatment with imipramine, alprazolam, or placebo." | 9.07 | Imipramine and alprazolam effects on stress test reactivity in panic disorder. ( Agras, WS; Ehlers, A; Haddad, JM; Maddock, RJ; Margraf, J; Roth, WT; Taylor, CB, 1992) |
| "To investigate whether alprazolam (ALP) coprescription early in the imipramine (IMI) treatment of panic disorder would improve overall treatment response to IMI alone, 48 panic disorder patients were randomly assigned to receive either IMI plus placebo or IMI plus ALP for 4-6 weeks, followed by 2 weeks of IMI plus placebo-ALP taper and 2 more weeks of IMI alone." | 9.07 | Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. ( Charney, DS; Heninger, GR; Koleszar, AS; Krystal, JH; Nagy, LM; Woods, SW, 1992) |
| "Several issues remain to be ascertained beyond the acute response to imipramine hydrochloride in patients with panic disorder." | 9.07 | Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. ( Mavissakalian, M; Perel, JM, 1992) |
| "This study was designed to assess and compare the differential relapse rates of patients with panic disorder and agoraphobia after discontinuation of acute treatment (6 months) or acute plus maintenance treatment (18 months) with imipramine." | 9.07 | Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. ( Mavissakalian, M; Perel, JM, 1992) |
| "The purpose of this study is to describe the clinical and light microscopic findings in 4 patients with imipramine-induced hyperpigmentation and to better understand its origin." | 8.80 | Imipramine-induced hyperpigmentation: four cases and a review of the literature. ( Bhawan, J; Cohen, LM; McCalmont, TH; Ming, ME; Stefanato, CM, 1999) |
| "Although imipramine is one of the antidepressants that could be effective in the treatment of panic disorder, data on its usage for this diagnosis in the pregnancy period are limited." | 7.80 | Low-dose imipramine for treatment of panic disorder during pregnancy: a retrospective chart review. ( Askin, R; Gungor, B; Sahingoz, M; Uguz, F, 2014) |
| "Nine patients with panic disorder and agoraphobia associated with chronic dizziness underwent otoneurological screening and were treated with a 3-months course of imipramine." | 7.77 | Imipramine for vestibular dysfunction in panic disorder: a prospective case series. ( Mathias, Kde V; Mezzasalma, MA; Nardi, AE; Nascimento, I; Valença, AM, 2011) |
| "To examine the medical costs and effectiveness of acute treatment with imipramine versus acute treatment plus 2 different maintenance therapies for panic disorder." | 7.70 | Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. ( Flynn, JA; Mavissakalian, MR; Revicki, DA; Schmier, JK, 2000) |
| "One hundred and ten consecutive patients with DSM-III-R moderate to severe panic disorder with agoraphobia were treated with a fixed regimen of imipramine 2." | 7.70 | Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM; Sloan, C; Talbott-Green, M, 1998) |
| " This case report deals with a patient with a long history of panic disturbances including agoraphobia, social phobia, depressive moods and alcohol abuse, whose condition remitted only after applying a supplementary treatment, using Imipramine and Moclobimide in conjunction with behavioural therapy." | 7.69 | [Treatment refractory panic disorder--success of a combined treatment with imipramine, moclobemide and behavior therapy]. ( Boerner, RJ, 1995) |
| "The authors report on seven consecutive openly treated patients with panic disorder who showed inadequate antipanic responses to treatment regimens including either a tricyclic (TCA) or fluoxetine." | 7.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "High affinity 3H-paroxetine and 3H-imipramine binding sites were simultaneously studied in platelets of 29 untreated patients with panic disorder and 12 healthy controls." | 7.69 | Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls. ( Faludi, G; Tekes, K; Tóthfalusi, L, 1994) |
| "Eleven panic disorder patients who panicked in response to exogenous cholecystokinin tetrapeptide (CCK-4) were rechallenged after chronic treatment with imipramine." | 7.69 | Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. ( Bradwejn, J; Koszycki, D, 1994) |
| "Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged." | 7.68 | Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. ( Charney, DS; Krystal, JH; Merikangas, KR; Nagy, LM; Woods, SW, 1993) |
| "The response to treatment with imipramine or clonazepam was evaluated in patients with panic disorder." | 7.68 | [Treatment of patients with panic disorder and an elevated urinary excretion of MHPG using imipramine or clonazepam]. ( Carreira, I; Casique, M; Lima, L; Morales, M; Silva, C, 1992) |
| "The most common pharmacological treatments for panic disorder with agoraphobia (PDA) include the use of imipramine and alprazolam while the most common behavior therapy is the use of graded in vivo exposure." | 7.68 | A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. ( Cox, BJ; Endler, NS; Lee, PS; Swinson, RP, 1992) |
| " These treatments were combined with imipramine or placebo for a total of eight experimental conditions." | 6.73 | Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. ( Borgeat, F; Coutu, MF; Dupuis, G; Fleet, R; Mainguy, N; Marchand, A; Todorov, C, 2008) |
| "Imipramine treatment (29 weeks) had no effect on alpha 2AR density or coupling, despite improvement in anxiety ratings." | 6.69 | Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. ( Antai-Otong, D; Blakeley, JE; Gurguis, GN; Orsulak, PJ; Petty, F; Rush, AJ; Vo, SP, 1999) |
| "Both imipramine and CBT were significantly superior to placebo for the acute treatment phase as assessed by the PDSS (response rates for the intent-to-treat [ITT] analysis, 45." | 6.69 | Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. ( Barlow, DH; Gorman, JM; Shear, MK; Woods, SW, 2000) |
| "Imipramine was gradually withdrawn after 6 months." | 6.67 | A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. ( Anastasiades, P; Clark, DM; Gelder, M; Hackmann, A; Middleton, H; Salkovskis, PM, 1994) |
| " If a side effect profile is known, it will be easier for a clinician to choose the right drug and the appropriate management by taking into account compliance, safety and efficacy in each patient under treatment." | 6.67 | Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. ( Benkert, O; Cassano, GB; Curtis, G; Deltito, J; Hippius, H; Klerman, G; Maier, W; Petracca, A; Shera, D; Toni, C, 1994) |
| "Alprazolam therapy was effective and well tolerated at a mean daily dose of 5." | 6.67 | Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| "Of 60 depressed alcoholics who completed an open trial of imipramine, 27 (45%) responded with improvement in both mood and drinking behavior, and eight (13%) responded after further dosage increases or treatment with disulfiram." | 6.67 | Imipramine treatment of alcoholism with comorbid depression. ( Harrison, W; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Stewart, JP; Tricamo, E, 1993) |
| "The etiology and optimum treatment of panic disorder remain unclear." | 6.39 | Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. ( Boyer, W, 1995) |
| "Cholecystokinin (CCK) is a neurotransmitter found in high density in the brains of mammals." | 6.38 | Neurobiological investigations into the role of cholecystokinin in panic disorder. ( Bradwejn, J, 1993) |
| "The prevalence of mitral valve prolapse (MVP) and panic disorder (PD) has been reported to range from 0-50% depending on the respective diagnostic manuals and described selection criteria." | 5.31 | Treatment of mitral valve prolapse and panic disorder with metoprolol. ( Baghai, T; Rupprecht, R; Schule, C; Zwanzger, P, 2000) |
| "Patients treated with imipramine plus CBT experienced less severe fatigue/weakness, dry mouth, and sweating and had a lower rate of dropout due to side effects compared with those treated with imipramine only." | 5.12 | A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy. ( Barlow, D; Goetz, R; Gorman, J; Gorman, L; Lewin, D; Marcus, SM; Martinez, J; Mosovich, S; Ray, S; Shear, MK; Woods, S, 2007) |
| "The authors explored the prognostic value of 3 different types of catastrophic cognitions in the treatment of panic disorder with and without mild-to-moderate agoraphobia using a sample of 143 participants who received either cognitive-behavioral therapy (CBT) or imipramine in a randomized controlled trial." | 5.11 | Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder. ( Barlow, DH; Gorman, JM; Hicks, TV; Leitenberg, H; Shear, MK; Woods, SW, 2005) |
| " In the context of a multicenter study that compared psychosocial and medication treatments for panic disorder, we assessed whether such characteristics as age of the psychiatrist, number of years of experience, and gender influence the outcome of treatment with the antipanic drug imipramine." | 5.10 | The effect of pharmacotherapist characteristics on treatment outcome in panic disorder. ( Barlow, DH; Goetz, R; Gorman, JM; Huppert, JD; Martinez, JM; Ray, S; Shear, MK; Woods, SW, 2003) |
| "To evaluate the efficacy and tolerability of sertraline and imipramine in patients with comorbid panic disorder and major depressive disorder." | 5.10 | Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. ( Arató, M; Austin, C; Lepola, U; Zhu, Y, 2003) |
| "Pretreatment with imipramine, buspirone, or placebo was compared in 40 patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition criteria for panic disorder and in patients who were discontinuing long-term benzodiazepine use." | 5.10 | Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy. ( García-España, F; Greenblatt, DJ; Mandos, LA; Rickels, K; Rynn, M; Schweizer, E, 2003) |
| "The study explored whether there is differential efficacy for patients with panic disorder treated with sertraline initially (primary group) versus those switched (transfer group) after intolerance or nonresponse to imipramine in the context of the open 24-week treatment phase of a long-term maintenance/discontinuation study." | 5.10 | Sertraline in panic disorder: initial treatment versus switch strategy. ( Mavissakalian, MR, 2003) |
| "In a recent study, the authors suggested that tachycardia, dry mouth, and sweating continued to burden patients with panic disorder with agoraphobia who have shown marked and stable response to 6 months of imipramine treatment at the fixed, weight-adjusted dose of 2." | 5.10 | Specific side effects of long-term imipramine management of panic disorder. ( Guo, S; Mavissakalian, M; Perel, J, 2002) |
| "It has been suggested that maintenance treatment of patients who have remitted panic disorder with agoraphobia beyond the six months of acute phase imipramine treatment may decrease the risk of relapse." | 5.10 | Duration of imipramine therapy and relapse in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 2002) |
| " The aim of the present study was to assess the 12-month cumulative risk of relapse specifically due to discontinuation of imipramine and to test the hypothesis that maintenance treatment with imipramine protects patients with panic disorder and agoraphobia from such reversals." | 5.09 | Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 1999) |
| " Thirty-seven outpatients with panic disorder and agoraphobia (PDA) were treated with imipramine (75-150 mg/day) in an 8-week open, prospective trial." | 5.09 | Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. ( Bandelow, B; Beinroth, D; Broocks, A; Brunner, E; Hajak, G; Pralle, L; Rüther, E, 1999) |
| "Our data suggest the comparable efficacy of alprazolam and imipramine in the short-term treatment of older adults with panic disorder." | 5.09 | Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. ( Sheikh, JI; Swales, PJ, 1999) |
| "In a recent study, the authors gauged the net effectiveness of imipramine to be 53%; that is, of 110 patients having panic disorder with agoraphobia who started a course of imipramine at a fixed, targeted, weight-adjusted dose of 2." | 5.09 | The side effects burden of extended imipramine treatment of panic disorder. ( Mavissakalian, MR; Perel, JM, 2000) |
| "The results from our 1 year placebo-controlled maintenance/discontinuation study in remitted panic disorder with agoraphobia patients confirmed the significant prophylactic effectiveness of imipramine maintenance treatment but suggested that this may be necessary in only 37% of the patients who relapse following discontinuation of 6 months acute imipramine treatment." | 5.09 | 2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM, 2001) |
| "Emotion-focused psychotherapy was less effective for symptoms of panic disorder than treatment with either cognitive behavior therapy or imipramine; results obtained with emotion-focused psychotherapy after the acute and maintenance phases were similar to those seen with placebo." | 5.09 | Emotion-focused psychotherapy for patients with panic disorder. ( Greeno, C; Houck, P; Masters, S; Shear, MK, 2001) |
| "50 patients with panic disorder (30 without and 20 with concomitant depression) were enrolled in a controlled treatment study using either imipramine or doxepin in addition to supportive psychotherapy and were then studied under naturalistic treatment conditions over a 5-year period." | 5.08 | Panic disorder with or without concomitant depression 5 years after treatment: a prospective follow-up. ( Albus, M; Scheibe, G; Scherer, J, 1995) |
| "The aim of this study was to characterize the specific effects of imipramine in the treatment of panic disorder with agoraphobia and to delineate dose-response and possibly plasma level-response relationships." | 5.08 | Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. ( Mavissakalian, MR; Perel, JM, 1995) |
| "After controlled treatment with either imipramine or doxepin with additional psychotherapy, 30 patients with pure panic disorder and 20 with concomitant depression were followed under ordinary treatment conditions over a 5-year period." | 5.08 | Fluctuation of symptoms and social functioning in panic disorder with or without concomitant depression. A 5-year prospective follow-up. ( Albus, M; Scheibe, G; Scherer, J, 1995) |
| "Cerebrospinal fluid (CSF) gamma-aminobutyric acid (GABA) levels were measured in 11 patients with panic disorder (PD) prior to and following 7 months of treatment with alprazolam or imipramine and in six neurological control patients." | 5.08 | Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. ( Halonen, T; Jolkkonen, J; Lepola, U; Riekkinen, P; Rimón, R, 1995) |
| "Forty-seven patients meeting DSM-III-R criteria for panic disorder with agoraphobia (PAG) were assessed by the Minnesota Multiphasic Personality Inventory (MMPI) at baseline and after 8 weeks of treatment with imipramine, clomipramine and placebo." | 5.08 | Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment. ( Gentil, V; Gorenstein, C; Ito, LM; Miyakawa, E, 1995) |
| " This study investigated the proposition that individual panic symptoms may also differ in their specific responsiveness to treatment in 63 patients with panic disorder with agoraphobia who had completed an 8-week placebo-controlled dose-ranging study with imipramine." | 5.08 | Phenomenology of panic attacks: responsiveness of individual symptoms to imipramine. ( Mavissakalian, MR, 1996) |
| "This report is a descriptive summary of the relationship between response and plasma tricyclic concentrations found in our previously reported dose-ranging study of imipramine (IMI) in panic disorder (Mavissakalian & Perel 1995)." | 5.08 | The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder. ( Mavissakalian, MR; Perel, JM, 1996) |
| "This study compared the efficacy, tolerability, and safety of fluvoxamine, imipramine, and placebo in the treatment of panic disorder with or without agoraphobia." | 5.08 | A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. ( Bakish, D; Charbonneau, Y; Filteau, MJ; Fraser, G; Hooper, CL; Raine, D; Thibaudeau, C; West, DL, 1996) |
| " We reanalyzed a study of 81 panic patients treated with placebo, alprazolam 2 mg or 6 mg, or imipramine 225 mg daily to investigate the effect of baseline pathology and selective effects of treatment on biological and cognitive components of panic disorder." | 5.08 | Growing placebo response rate: the problem in recent therapeutic trials? ( Matuzas, W; Thompson, PM; Uhlenhuth, EH; Warner, TD, 1997) |
| "Fluvoxamine and imipramine were compared to placebo in an 8-week doubleblind randomized multicentre trial comprising of 148 outpatients between 19 and 57 years of age (mean: 35) with a DSM-III-R diagnosis of Panic Disorder." | 5.08 | Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. ( Amin, M; Bakish, D; Nair, NP; Saxena, B; Schwartz, G; West, TE, 1996) |
| " The present study reports on the degree and sources of pretreatment attrition at two sites of a multicenter study on panic disorder that compared treatment outcomes for imipramine and cognitive behavior therapy." | 5.08 | Pretreatment attrition in a comparative treatment outcome study on panic disorder. ( Barlow, DH; Detweiler, MF; Gorman, JM; Hofmann, SG; Papp, LA; Ray, SE; Shear, MK; Woods, SW, 1998) |
| "Ninety-three patients with panic disorder and mild or no agoraphobia were treated for their panic disorder by using either 11 sessions of individual cognitive-behavior therapy or imipramine." | 5.08 | Effects of panic disorder treatments on personality disorder characteristics. ( Barlow, DH; Gorman, JM; Hershberger, D; Hofmann, SG; Patterson, M; Shear, MK; Woods, SW, 1998) |
| "An independent group of panic disorder patients placed on imipramine was studied with positron-emission tomography, testing for evidence of normalization versus persistence of the abnormal rCMRglc ratios." | 5.08 | Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorders. ( Andreason, P; Benkelfat, C; Cohen, RM; Nordahl, TE; Semple, WE; Stein, MB; Uhde, TW; Zametkin, A, 1998) |
| "This article presents panic diary results of a dose-response study with imipramine hydrochloride in panic disorder with agoraphobia patients." | 5.07 | Dose-response characterization of the antipanic effects of imipramine. ( Mavissakalian, MR; Perel, JM, 1994) |
| "Forty Danish panic disorder patients participating in a placebo controlled study of alprazolam and imipramine (The Cross National Collaborative Panic Study, Phase II) were followed up by a telephone interview three years later, with essentially the same battery of evaluation procedures applied at baseline, end of study, and follow-up." | 5.07 | Three years follow-up of panic disorder patients: a naturalistic study. ( Rosenberg, NK; Rosenberg, R, 1994) |
| "This study examines clinical predictors of outcome for patients with panic disorder and depression in a 16 week, placebo-controlled trial of alprazolam and imipramine (n = 126)." | 5.07 | Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. ( Deltito, JA; Keller, MB; Leon, A; Otto, MW; Pollack, MH; Rosenbaum, JF; Sachs, GS; Shear, MK, 1994) |
| " The group with prominent respiratory symptoms suffered more spontaneous panic attacks and responded to imipramine, whereas the group without prominent respiratory symptoms suffered more situational panic attacks and responded more to alprazolam." | 5.07 | Subtyping of panic disorder by symptom profile. ( Brandon, S; Briggs, AC; Stretch, DD, 1993) |
| " The present study provided systematic data from a double blind comparison of maintenance therapy (up to 8 months) of panic disorder with or without agoraphobia with alprazolam, imipramine, or placebo in 181 patients who had responded to the same regimen in a randomized 8-week treatment trial." | 5.07 | Maintenance drug therapy of panic disorder. ( Ayuso, JL; Cassano, GB; Curtis, GC; Massana, J; Perugi, G; Udina, C, 1993) |
| "This article reports the effects of imipramine on heart rate and blood pressure in panic disorder patients who participated in an 8-week double-blind dosage response treatment protocol." | 5.07 | Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm. ( de Groot, CM; Mavissakalian, MR, 1994) |
| "Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment." | 5.07 | Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine. ( Lepola, UM; Riekkinen, PJ; Rimón, RH, 1993) |
| "Forty-eight patients with panic disorder completing 8 months of maintenance treatment with alprazolam (mean dose, 5." | 5.07 | Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| "To examine the effect of treatment on lactate-induced anxiety in a controlled study, we infused 44 panic disorder patients with lactate and placebo before and after eight weeks of double-blind treatment with imipramine, diazepam, or placebo." | 5.07 | Lactate-induced anxiety after imipramine and diazepam treatment. ( Balon, R; Berchou, R; Lycaki, H; Pohl, R, 1994) |
| "The present study is aimed at assessing a 48-outpatient sample that had been diagnosed as Panic Disorder cases: Approximately 5 years ago, patients had been treated with either Alprazolam, Imipramine or placebo during an 8-week double-blind trial." | 5.07 | [Patients with panic disorder: a 5-year follow-up study]. ( Arévalo, W; Gaviria, LF; Leon, A; León, CA, 1992) |
| "A double-blind, placebo-controlled trial was undertaken to compare the effects of imipramine and clomipramine in the treatment of panic disorder with or without agoraphobia." | 5.07 | Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. ( Eriksson, E; Modigh, K; Westberg, P, 1992) |
| "The reactivity of 40 panic disorder patients on mental arithmetic, cold pressor, and 5% CO2 inhalation stressors was tested before and after 8 weeks of treatment with imipramine, alprazolam, or placebo." | 5.07 | Imipramine and alprazolam effects on stress test reactivity in panic disorder. ( Agras, WS; Ehlers, A; Haddad, JM; Maddock, RJ; Margraf, J; Roth, WT; Taylor, CB, 1992) |
| "To investigate whether alprazolam (ALP) coprescription early in the imipramine (IMI) treatment of panic disorder would improve overall treatment response to IMI alone, 48 panic disorder patients were randomly assigned to receive either IMI plus placebo or IMI plus ALP for 4-6 weeks, followed by 2 weeks of IMI plus placebo-ALP taper and 2 more weeks of IMI alone." | 5.07 | Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. ( Charney, DS; Heninger, GR; Koleszar, AS; Krystal, JH; Nagy, LM; Woods, SW, 1992) |
| "Several issues remain to be ascertained beyond the acute response to imipramine hydrochloride in patients with panic disorder." | 5.07 | Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. ( Mavissakalian, M; Perel, JM, 1992) |
| "This study was designed to assess and compare the differential relapse rates of patients with panic disorder and agoraphobia after discontinuation of acute treatment (6 months) or acute plus maintenance treatment (18 months) with imipramine." | 5.07 | Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. ( Mavissakalian, M; Perel, JM, 1992) |
| "The impact of the avoidance behaviour on the psychopharmacological treatment of panic disorder was explored in the Cross National Collaborative Panic Study (n = 1134 patients); in this double blind randomized trial alprazolam, imipramine and placebo were compared during an 8-week treatment period." | 5.07 | Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder? ( Argyle, N; Benkert, O; Brandon, S; Buller, R; Lavori, P; Maier, W; Roth, SM, 1991) |
| " Because imipramine has lowered T4 in uncontrolled studies we examined the effect of imipramine on serum thyroid levels in panic disorder patients in a double-blind placebo and diazepam treatment controlled study." | 5.07 | The changes of thyroid hormone during pharmacological treatment of panic disorder patients. ( Balon, R; Glitz, DA; Pohl, R; Ramesh, C; Yeragani, VK, 1991) |
| " In this paper, we selectively review the author's research with the standard antidepressant, imipramine, in the treatment of panic disorder with agoraphobia as it relates to practical issues." | 4.80 | Rational treatment of panic disorder with antidepressants. ( Mavissakalian, MR; Ryan, MT, 1998) |
| "The purpose of this study is to describe the clinical and light microscopic findings in 4 patients with imipramine-induced hyperpigmentation and to better understand its origin." | 4.80 | Imipramine-induced hyperpigmentation: four cases and a review of the literature. ( Bhawan, J; Cohen, LM; McCalmont, TH; Ming, ME; Stefanato, CM, 1999) |
| "Although imipramine is one of the antidepressants that could be effective in the treatment of panic disorder, data on its usage for this diagnosis in the pregnancy period are limited." | 3.80 | Low-dose imipramine for treatment of panic disorder during pregnancy: a retrospective chart review. ( Askin, R; Gungor, B; Sahingoz, M; Uguz, F, 2014) |
| "Nine patients with panic disorder and agoraphobia associated with chronic dizziness underwent otoneurological screening and were treated with a 3-months course of imipramine." | 3.77 | Imipramine for vestibular dysfunction in panic disorder: a prospective case series. ( Mathias, Kde V; Mezzasalma, MA; Nardi, AE; Nascimento, I; Valença, AM, 2011) |
| "A 40-year-old female with a 3-year history of panic disorder was prescribed fluvoxamine 50 mg day(-1) in addition to clorazepate dipotassium and sulpiride." | 3.74 | Piloerection induced by replacing fluvoxamine with milnacipran. ( Hazui, T; Hori, S; Matsuo, N; Miki, A; Nakano, M; Ohtani, H; Sawada, Y; Suzuki, Y; Yagi, H; Yamamoto, A, 2007) |
| "To examine the medical costs and effectiveness of acute treatment with imipramine versus acute treatment plus 2 different maintenance therapies for panic disorder." | 3.70 | Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. ( Flynn, JA; Mavissakalian, MR; Revicki, DA; Schmier, JK, 2000) |
| "One hundred and ten consecutive patients with DSM-III-R moderate to severe panic disorder with agoraphobia were treated with a fixed regimen of imipramine 2." | 3.70 | Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. ( Mavissakalian, MR; Perel, JM; Sloan, C; Talbott-Green, M, 1998) |
| "Cardiovascular measures (spectral derivatives of heart rate variability, the blood pressure response to standing and plasma noradrenaline levels) have been shown to change as clinical recovery follows the treatment of panic disorder patients with either imipramine or cognitive therapy." | 3.69 | Clinical recovery from panic disorder is associated with evidence of changes in cardiovascular regulation. ( Ashby, M; Middleton, HC, 1995) |
| " This case report deals with a patient with a long history of panic disturbances including agoraphobia, social phobia, depressive moods and alcohol abuse, whose condition remitted only after applying a supplementary treatment, using Imipramine and Moclobimide in conjunction with behavioural therapy." | 3.69 | [Treatment refractory panic disorder--success of a combined treatment with imipramine, moclobemide and behavior therapy]. ( Boerner, RJ, 1995) |
| "We measured platelet [3H]imipramine and [3H]paroxetine binding in patients with major depression (n = 11), dysthymia (n = 9), generalized anxiety (n = 18) and panic disorder (n = 10), and in healthy controls (n = 13)." | 3.69 | Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. ( Bernier, B; Iny, LJ; Luthe, L; Meaney, MJ; Nair, NP; Pecknold, J; Suranyi-Cadotte, BE, 1994) |
| "The authors report on seven consecutive openly treated patients with panic disorder who showed inadequate antipanic responses to treatment regimens including either a tricyclic (TCA) or fluoxetine." | 3.69 | Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. ( Coplan, JD; Gorman, JM; Papp, LA; Tiffon, L, 1994) |
| "High affinity 3H-paroxetine and 3H-imipramine binding sites were simultaneously studied in platelets of 29 untreated patients with panic disorder and 12 healthy controls." | 3.69 | Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls. ( Faludi, G; Tekes, K; Tóthfalusi, L, 1994) |
| "Eleven panic disorder patients who panicked in response to exogenous cholecystokinin tetrapeptide (CCK-4) were rechallenged after chronic treatment with imipramine." | 3.69 | Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. ( Bradwejn, J; Koszycki, D, 1994) |
| "In the treatment of panic disorder double-blind controlled studies have demonstrated that imipramine (IMI) was effective at doses higher than 125 mg/day." | 3.69 | The treatment of panic disorder in a clinical setting: a 12-month naturalistic study. ( Ampollini, P; Maggini, C; Marchesi, C; Signifredi, R, 1997) |
| "The escape behaviour induced in rats by injecting D,L-homocysteic acid (DHL) into the dorsal periaqueductal grey area (DPAG) was used as an animal model of panic attacks to investigate the effect of imipramine, a drug used for the treatment of panic disorder, on the sensitivity of 5-HT1A receptors in the DPAG." | 3.69 | Effect of imipramine treatments on the 5-HT1A-receptor-mediated inhibition of panic-like behaviours in rats. ( Marsden, CA; Mongeau, R, 1997) |
| "Twenty-eight patients with a DSM-III diagnosis of agoraphobia with panic attacks who completed a 4-month combined drug and behavioral treatment program and who were then discharged on imipramine were interviewed 1 to 5 years after being discharged." | 3.68 | Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study. ( Charney, DS; Krystal, JH; Merikangas, KR; Nagy, LM; Woods, SW, 1993) |
| " Further attacks after discharge were recognized as panic attacks, and resolved with the anti-depressant imipramine." | 3.68 | Panic disorder masquerading as pre-eclampsia. ( Benjamin, J; Benjamin, M, 1993) |
| "The response to treatment with imipramine or clonazepam was evaluated in patients with panic disorder." | 3.68 | [Treatment of patients with panic disorder and an elevated urinary excretion of MHPG using imipramine or clonazepam]. ( Carreira, I; Casique, M; Lima, L; Morales, M; Silva, C, 1992) |
| "The most common pharmacological treatments for panic disorder with agoraphobia (PDA) include the use of imipramine and alprazolam while the most common behavior therapy is the use of graded in vivo exposure." | 3.68 | A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. ( Cox, BJ; Endler, NS; Lee, PS; Swinson, RP, 1992) |
| "Painful ejaculation following the administration of imipramine and clomipramine is described in four patients." | 3.68 | Painful ejaculation associated with antidepressants in four patients. ( Aizenberg, D; Hermesh, H; Karp, L; Weizman, A; Zemishlany, Z, 1991) |
| " These treatments were combined with imipramine or placebo for a total of eight experimental conditions." | 2.73 | Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. ( Borgeat, F; Coutu, MF; Dupuis, G; Fleet, R; Mainguy, N; Marchand, A; Todorov, C, 2008) |
| "Imipramine treatment (29 weeks) had no effect on alpha 2AR density or coupling, despite improvement in anxiety ratings." | 2.69 | Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. ( Antai-Otong, D; Blakeley, JE; Gurguis, GN; Orsulak, PJ; Petty, F; Rush, AJ; Vo, SP, 1999) |
| "Both imipramine and CBT were significantly superior to placebo for the acute treatment phase as assessed by the PDSS (response rates for the intent-to-treat [ITT] analysis, 45." | 2.69 | Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. ( Barlow, DH; Gorman, JM; Shear, MK; Woods, SW, 2000) |
| "The course of panic disorder is not uniform." | 2.68 | Long-term follow-up after a drug trial for panic disorder. ( Amering, M; Ballenger, JC; Briggs, A; Buller, R; Cassano, G; Garvey, M; Katschnig, H; Klerman, GL; Roth, M; Stolk, JM, 1995) |
| "Imipramine was gradually withdrawn after 6 months." | 2.67 | A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. ( Anastasiades, P; Clark, DM; Gelder, M; Hackmann, A; Middleton, H; Salkovskis, PM, 1994) |
| " If a side effect profile is known, it will be easier for a clinician to choose the right drug and the appropriate management by taking into account compliance, safety and efficacy in each patient under treatment." | 2.67 | Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo. ( Benkert, O; Cassano, GB; Curtis, G; Deltito, J; Hippius, H; Klerman, G; Maier, W; Petracca, A; Shera, D; Toni, C, 1994) |
| "Alprazolam therapy was effective and well tolerated at a mean daily dose of 5." | 2.67 | Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. ( Rickels, K; Schweizer, E; Weiss, S; Zavodnick, S, 1993) |
| "Of 60 depressed alcoholics who completed an open trial of imipramine, 27 (45%) responded with improvement in both mood and drinking behavior, and eight (13%) responded after further dosage increases or treatment with disulfiram." | 2.67 | Imipramine treatment of alcoholism with comorbid depression. ( Harrison, W; McGrath, PJ; Nunes, EV; Ocepek-Welikson, K; Quitkin, FM; Stewart, JP; Tricamo, E, 1993) |
| "Help-seeking behaviour for treatment of panic disorder was investigated in the sample of the Cross-National Collaborative Panic Study Second Phase." | 2.67 | Center differences and cross-national invariance in help-seeking for panic disorder. A report from the cross-national collaborative panic study. ( Amering, M; Buller, R; Deltito, JA; Katschnig, H; Klerman, GL; Lavori, PW; Winter, P, 1992) |
| "Panic disorder is characterised by recurrent unexpected panic attacks consisting of a wave of intense fear that reaches a peak within a few minutes." | 2.61 | Benzodiazepines versus placebo for panic disorder in adults. ( Barbui, C; Bighelli, I; Breilmann, J; Castellazzi, M; Cipriani, A; Davies, SJ; Furukawa, TA; Girlanda, F; Guaiana, G; Koesters, M, 2019) |
| "Antidepressants have been used to treat patients with panic disorder almost since these drugs were first introduced." | 2.40 | Antidepressants in panic disorder. ( Jefferson, JW, 1997) |
| "The etiology and optimum treatment of panic disorder remain unclear." | 2.39 | Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. ( Boyer, W, 1995) |
| "Drug treatment of panic disorder is reviewed with focus on recent controlled studies." | 2.38 | Drug treatment of panic disorder. ( Rosenberg, R, 1993) |
| "Cholecystokinin (CCK) is a neurotransmitter found in high density in the brains of mammals." | 2.38 | Neurobiological investigations into the role of cholecystokinin in panic disorder. ( Bradwejn, J, 1993) |
| "The prevalence of mitral valve prolapse (MVP) and panic disorder (PD) has been reported to range from 0-50% depending on the respective diagnostic manuals and described selection criteria." | 1.31 | Treatment of mitral valve prolapse and panic disorder with metoprolol. ( Baghai, T; Rupprecht, R; Schule, C; Zwanzger, P, 2000) |
| "Posttraumatic stress disorder (PTSD) is frequently associated with major depressive disorder, and antidepressants have been reported to ameliorate PTSD symptoms in some patients." | 1.29 | Platelet imipramine binding in patients with posttraumatic stress disorder before and after phenelzine treatment. ( Abramovitz-Schnaider, P; Freudstein-Dan, A; Laor, N; Rehavi, M; Schujovitsky, A; Weizman, R; Wolmer, L, 1996) |
| "Imipramine (IMI) treatment yielded complete remission of her symptoms for three years." | 1.29 | Panic attacks, complex partial seizures, and multiple meningiomas. ( Nickell, PV, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 105 (73.43) | 18.2507 |
| 2000's | 29 (20.28) | 29.6817 |
| 2010's | 8 (5.59) | 24.3611 |
| 2020's | 1 (0.70) | 2.80 |
| Authors | Studies |
|---|---|
| Maraschin, JC | 1 |
| Sestile, CC | 1 |
| Yabiku, CT | 1 |
| Roncon, CM | 1 |
| de Souza Fiaes, GC | 1 |
| Graeff, FG | 1 |
| Audi, EA | 2 |
| Zangrossi, H | 1 |
| Breilmann, J | 1 |
| Girlanda, F | 1 |
| Guaiana, G | 1 |
| Barbui, C | 1 |
| Cipriani, A | 1 |
| Castellazzi, M | 1 |
| Bighelli, I | 1 |
| Davies, SJ | 1 |
| Furukawa, TA | 2 |
| Koesters, M | 1 |
| Uguz, F | 2 |
| Sahingoz, M | 1 |
| Gungor, B | 1 |
| Askin, R | 1 |
| Aydin, A | 1 |
| Ak, M | 1 |
| Turgut, K | 1 |
| Marchand, A | 1 |
| Coutu, MF | 1 |
| Dupuis, G | 1 |
| Fleet, R | 1 |
| Borgeat, F | 1 |
| Todorov, C | 1 |
| Mainguy, N | 1 |
| Raffa, SD | 1 |
| Stoddard, JA | 1 |
| White, KS | 1 |
| Barlow, DH | 9 |
| Gorman, JM | 12 |
| Shear, MK | 14 |
| Woods, SW | 11 |
| Katherine Shear, M | 1 |
| Money, R | 1 |
| Etschel, E | 1 |
| Engel, RR | 1 |
| Leucht, S | 1 |
| Mezzasalma, MA | 3 |
| Mathias, Kde V | 3 |
| Nascimento, I | 3 |
| Valença, AM | 3 |
| Nardi, AE | 3 |
| Roberson-Nay, R | 1 |
| Latendresse, SJ | 1 |
| Kendler, KS | 1 |
| Diniz, L | 1 |
| Dos Reis, BB | 1 |
| de Castro, GM | 1 |
| Medalha, CC | 1 |
| Viana, MB | 1 |
| Biesdorf, C | 1 |
| Cortez, DA | 1 |
| Zwanzger, P | 1 |
| Baghai, T | 1 |
| Schule, C | 1 |
| Rupprecht, R | 2 |
| Martinez, JM | 2 |
| Goetz, R | 2 |
| Huppert, JD | 1 |
| Ray, S | 2 |
| Lepola, U | 3 |
| Arató, M | 1 |
| Zhu, Y | 1 |
| Austin, C | 1 |
| Mavissakalian, MR | 14 |
| Perel, JM | 10 |
| Rynn, M | 1 |
| García-España, F | 1 |
| Greenblatt, DJ | 1 |
| Mandos, LA | 1 |
| Schweizer, E | 4 |
| Rickels, K | 4 |
| Andersch, S | 1 |
| Hetta, J | 1 |
| Heuzenroeder, L | 1 |
| Donnelly, M | 1 |
| Haby, MM | 1 |
| Mihalopoulos, C | 1 |
| Rossell, R | 1 |
| Carter, R | 1 |
| Andrews, G | 1 |
| Vos, T | 1 |
| Schmier, JK | 1 |
| Flynn, JA | 1 |
| Revicki, DA | 1 |
| Hicks, TV | 1 |
| Leitenberg, H | 1 |
| Uhlenhuth, EH | 2 |
| Leon, AC | 6 |
| Matuzas, W | 2 |
| Marcus, SM | 1 |
| Gorman, J | 1 |
| Lewin, D | 1 |
| Martinez, J | 2 |
| Mosovich, S | 1 |
| Gorman, L | 1 |
| Barlow, D | 1 |
| Woods, S | 1 |
| Hori, S | 1 |
| Matsuo, N | 1 |
| Yamamoto, A | 1 |
| Hazui, T | 1 |
| Yagi, H | 1 |
| Nakano, M | 1 |
| Suzuki, Y | 1 |
| Miki, A | 1 |
| Ohtani, H | 1 |
| Sawada, Y | 1 |
| Hofmann, SG | 3 |
| Meuret, AE | 1 |
| Rosenfield, D | 1 |
| Suvak, MK | 1 |
| McHugh, RK | 1 |
| Otto, MW | 3 |
| Pollack, MH | 5 |
| Rosenbaum, JF | 6 |
| Keller, MB | 3 |
| Marzuk, PM | 1 |
| Portera, L | 4 |
| Boyer, W | 1 |
| Albus, M | 5 |
| Scheibe, G | 5 |
| Scherer, J | 2 |
| Boerner, RJ | 2 |
| Middleton, HC | 1 |
| Ashby, M | 1 |
| Pecknold, JC | 1 |
| Luthe, L | 2 |
| Iny, L | 1 |
| Ramdoyal, D | 1 |
| Shekhar, A | 1 |
| Watanabe, TK | 1 |
| Sylvester, CE | 1 |
| Manaligod, JM | 1 |
| Rosenberg, NK | 1 |
| Rosenberg, R | 2 |
| Clark, DM | 2 |
| Salkovskis, PM | 1 |
| Hackmann, A | 1 |
| Middleton, H | 1 |
| Anastasiades, P | 1 |
| Gelder, M | 1 |
| Iny, LJ | 1 |
| Pecknold, J | 1 |
| Suranyi-Cadotte, BE | 1 |
| Bernier, B | 1 |
| Nair, NP | 2 |
| Meaney, MJ | 1 |
| Sachs, GS | 2 |
| Leon, A | 3 |
| Deltito, JA | 3 |
| Kaspi, SP | 1 |
| Hammerness, PG | 1 |
| Briggs, AC | 1 |
| Stretch, DD | 1 |
| Brandon, S | 2 |
| Tiffon, L | 1 |
| Coplan, JD | 3 |
| Papp, LA | 4 |
| Nagy, LM | 2 |
| Krystal, JH | 2 |
| Charney, DS | 2 |
| Merikangas, KR | 1 |
| Bradwejn, J | 2 |
| Curtis, GC | 1 |
| Massana, J | 1 |
| Udina, C | 1 |
| Ayuso, JL | 2 |
| Cassano, GB | 3 |
| Perugi, G | 2 |
| Gelder, MG | 1 |
| Salkovskis, P | 1 |
| de Groot, CM | 1 |
| Faludi, G | 1 |
| Tekes, K | 1 |
| Tóthfalusi, L | 1 |
| Toni, C | 3 |
| Petracca, A | 1 |
| Deltito, J | 1 |
| Benkert, O | 2 |
| Curtis, G | 1 |
| Hippius, H | 1 |
| Maier, W | 3 |
| Shera, D | 2 |
| Klerman, G | 1 |
| Klerman, GL | 4 |
| Goldenberg, I | 1 |
| Benjamin, J | 1 |
| Benjamin, M | 1 |
| Koszycki, D | 1 |
| Lavori, PW | 3 |
| Goldenberg, IM | 1 |
| Baker, LA | 1 |
| Shear, K | 1 |
| Lepola, UM | 1 |
| Rimón, RH | 1 |
| Riekkinen, PJ | 1 |
| Weiss, S | 2 |
| Zavodnick, S | 2 |
| Balon, R | 5 |
| Yeragani, VK | 4 |
| Pohl, R | 5 |
| Merlos, B | 2 |
| Sherwood, P | 1 |
| Nunes, EV | 1 |
| McGrath, PJ | 1 |
| Quitkin, FM | 1 |
| Stewart, JP | 1 |
| Harrison, W | 1 |
| Tricamo, E | 1 |
| Ocepek-Welikson, K | 1 |
| Dawson, R | 1 |
| Rimón, R | 1 |
| Jolkkonen, J | 1 |
| Halonen, T | 1 |
| Riekkinen, P | 1 |
| Ito, LM | 1 |
| Gorenstein, C | 1 |
| Gentil, V | 1 |
| Miyakawa, E | 1 |
| Koponen, H | 1 |
| Leinonen, E | 1 |
| Katschnig, H | 3 |
| Amering, M | 3 |
| Stolk, JM | 2 |
| Ballenger, JC | 2 |
| Briggs, A | 1 |
| Buller, R | 4 |
| Cassano, G | 1 |
| Garvey, M | 1 |
| Roth, M | 1 |
| Weizman, R | 1 |
| Laor, N | 1 |
| Schujovitsky, A | 1 |
| Wolmer, L | 1 |
| Abramovitz-Schnaider, P | 1 |
| Freudstein-Dan, A | 1 |
| Rehavi, M | 1 |
| Jacobson, NS | 1 |
| Hollon, SD | 1 |
| Pollock, RA | 1 |
| Bakish, D | 2 |
| Hooper, CL | 1 |
| Filteau, MJ | 1 |
| Charbonneau, Y | 1 |
| Fraser, G | 1 |
| West, DL | 1 |
| Thibaudeau, C | 1 |
| Raine, D | 1 |
| Milrod, B | 1 |
| Busch, F | 1 |
| Tanay, VA | 1 |
| Glencorse, TA | 1 |
| Greenshaw, AJ | 1 |
| Baker, GB | 1 |
| Bateson, AN | 1 |
| Jefferson, JW | 1 |
| Olfson, M | 1 |
| Warner, TD | 1 |
| Thompson, PM | 1 |
| Fava, GA | 1 |
| Savron, G | 1 |
| Zielezny, M | 1 |
| Grandi, S | 1 |
| Rafanelli, C | 1 |
| Conti, S | 1 |
| Brown, TM | 1 |
| Gurguis, GN | 2 |
| Nickell, PV | 1 |
| Berchou, R | 1 |
| Lycaki, H | 1 |
| Saxena, B | 1 |
| Amin, M | 1 |
| Schwartz, G | 1 |
| West, TE | 1 |
| Marchesi, C | 1 |
| Ampollini, P | 1 |
| Signifredi, R | 1 |
| Maggini, C | 1 |
| Mongeau, R | 1 |
| Marsden, CA | 1 |
| Browne, ST | 2 |
| Welkowitz, L | 1 |
| Goetz, RR | 1 |
| Kent, J | 1 |
| Klein, DF | 2 |
| Detweiler, MF | 1 |
| Ray, SE | 1 |
| Talbott-Green, M | 1 |
| Sloan, C | 1 |
| Hershberger, D | 1 |
| Patterson, M | 1 |
| Nordahl, TE | 1 |
| Stein, MB | 1 |
| Benkelfat, C | 1 |
| Semple, WE | 1 |
| Andreason, P | 1 |
| Zametkin, A | 1 |
| Uhde, TW | 1 |
| Cohen, RM | 1 |
| Antai-Otong, D | 1 |
| Vo, SP | 1 |
| Blakeley, JE | 1 |
| Orsulak, PJ | 1 |
| Petty, F | 1 |
| Rush, AJ | 1 |
| Ryan, MT | 1 |
| Ming, ME | 1 |
| Bhawan, J | 1 |
| Stefanato, CM | 1 |
| McCalmont, TH | 1 |
| Cohen, LM | 1 |
| Bandelow, B | 2 |
| Brunner, E | 2 |
| Beinroth, D | 2 |
| Pralle, L | 2 |
| Broocks, A | 2 |
| Hajak, G | 2 |
| Rüther, E | 2 |
| Ströhle, A | 1 |
| Sheikh, JI | 1 |
| Swales, PJ | 1 |
| Glass, RM | 1 |
| Schatzberg, AF | 1 |
| Bertani, A | 1 |
| Perna, G | 1 |
| Arancio, C | 1 |
| Caldirola, D | 1 |
| Bellodi, L | 1 |
| Frare, F | 1 |
| Mata, B | 1 |
| Vitale, B | 1 |
| Mengali, F | 1 |
| Recchia, M | 1 |
| Serra, G | 1 |
| Akiskal, HS | 1 |
| Houck, P | 1 |
| Greeno, C | 1 |
| Masters, S | 1 |
| Kent, JM | 1 |
| Sullivan, GM | 1 |
| Kleber, M | 1 |
| Perepletchikova, F | 1 |
| Fyer, AJ | 1 |
| Mavissakalian, M | 3 |
| Perel, J | 1 |
| Guo, S | 1 |
| León, CA | 1 |
| Arévalo, W | 1 |
| Gaviria, LF | 1 |
| McCann, UD | 1 |
| Ricaurte, GA | 1 |
| Lima, L | 1 |
| Carreira, I | 1 |
| Morales, M | 1 |
| Silva, C | 1 |
| Casique, M | 1 |
| Bech, P | 1 |
| Allerup, P | 1 |
| Lavori, P | 2 |
| Nutzinger, D | 1 |
| Walther, AU | 1 |
| Ramesh, C | 3 |
| Glitz, D | 1 |
| Weinberg, P | 2 |
| Cox, BJ | 1 |
| Endler, NS | 1 |
| Lee, PS | 1 |
| Swinson, RP | 1 |
| Musetti, L | 1 |
| Modigh, K | 2 |
| Westberg, P | 2 |
| Eriksson, E | 2 |
| Roth, WT | 1 |
| Margraf, J | 1 |
| Ehlers, A | 1 |
| Haddad, JM | 1 |
| Maddock, RJ | 1 |
| Agras, WS | 1 |
| Taylor, CB | 1 |
| Koleszar, AS | 1 |
| Heninger, GR | 1 |
| Schreier, HA | 1 |
| Preskorn, SH | 1 |
| Fast, GA | 1 |
| Winter, P | 1 |
| Aizenberg, D | 1 |
| Zemishlany, Z | 1 |
| Hermesh, H | 1 |
| Karp, L | 1 |
| Weizman, A | 1 |
| Roth, SM | 1 |
| Argyle, N | 2 |
| Lisjö, P | 1 |
| Judd, FK | 1 |
| Burrows, GD | 1 |
| Norman, TR | 1 |
| Clark, DB | 1 |
| Glitz, DA | 1 |
| Solyom, C | 1 |
| Solyom, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study to Investigate the Effect of Administration of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation[NCT05470465] | Phase 1 | 27 participants (Actual) | Interventional | 2022-09-01 | Completed | ||
| Treatment of Panic Disorder: Long Term Strategies[NCT00000368] | Phase 3 | 379 participants (Actual) | Interventional | 1999-02-28 | Completed | ||
| Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder (PD) With Comorbid Major Depression[NCT00521352] | Phase 2 | 25 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Patient-centered Treatment of Anxiety After Low-Risk Chest Pain in the Emergency Room[NCT04811521] | 375 participants (Anticipated) | Interventional | 2021-04-01 | Enrolling by invitation | |||
| Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding[NCT01451697] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2011-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Minimum CGI-S score: 1 Maximum CGI-S score: 7~Higher scores indicate the presence of high symptom severity. Decrease in scores from baseline reflects clinical symptom improvement.~Patients will be classified as responders with a CGI-S = 1 or 2; and partial responders CGI-S = 3.~= Normal, not at all ill~= Borderline mentally ill~= Mildly ill~= Moderately ill~= Markedly ill~= Severely ill~= Among the most extremely ill patients" (NCT00521352)
Timeframe: 4 weeks
| Intervention | responders (CGI-S = 1 or 2) (Number) |
|---|---|
| Active | 6 |
| Sham | 1 |
"The Hamilton Rating Scale for Depression (HRSD) is a multiple item questionnaire used to provide an indication of depression severity. The 28-, rather then 17- or 24-, item version was used to assess subjects in this protocol.~28-item minimum score = 0 28-item maximum score = 84~Higher scores indicate high levels of symptomatology. Reduction in score from baseline indicates clinical symptom improvement." (NCT00521352)
Timeframe: 4 weeks
| Intervention | responders (Number) |
|---|---|
| Active | 3 |
| Sham | 1 |
"The Panic Disorder Severity Scale is a questionnaire developed for measuring the severity of panic disorder symptoms.~The PDSS consists of seven items, each rated on a 5-point scale, which ranges from 0 to 4. The items assess panic frequency, resulting distress, panic-focused anticipatory anxiety, phobic avoidance of situations and of physical sensations, impairment in occupational and social functioning. The overall assessment is made by a total score, which is calculated by summing the scores for all seven items. The total scores range from 0 to 28.~Higher scores indicate high levels of panic symptomatology. Reduction in score from baseline indicates clinical improvement of panic symptoms." (NCT00521352)
Timeframe: 4 weeks
| Intervention | responders (Number) |
|---|---|
| Active | 6 |
| Sham | 1 |
14 reviews available for imipramine and Panic Disorder
| Article | Year |
|---|---|
Benzodiazepines versus placebo for panic disorder in adults.
Topics: Adult; Aged; Agoraphobia; Benzodiazepines; Buspirone; Humans; Imipramine; Middle Aged; Numbers Neede | 2019 |
Cost-effectiveness of psychological and pharmacological interventions for generalized anxiety disorder and panic disorder.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Australia; Cost-Benefit Analysis; Cyclohexanols | 2004 |
Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis.
Topics: Alprazolam; Double-Blind Method; Humans; Imipramine; Panic Disorder; Prospective Studies; Psychiatri | 1995 |
Drug treatment of panic disorder.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Humans; Imipramine; Panic Disorder | 1993 |
Neurobiological investigations into the role of cholecystokinin in panic disorder.
Topics: Amino Acid Sequence; Base Sequence; Benzodiazepines; Brain; Cerebrovascular Circulation; Cholecystok | 1993 |
Cognitive treatment for panic disorder.
Topics: Alprazolam; Arousal; Clinical Trials as Topic; Cognitive Behavioral Therapy; Humans; Imipramine; Pan | 1993 |
Cognitive-behavior therapy versus pharmacotherapy: Now that the jury's returned its verdict, it's time to present the rest of the evidence.
Topics: Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Depressive Disorder; Humans; Imipram | 1996 |
Clinical issues in the long-term treatment of panic disorder.
Topics: Age Factors; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Child; Cognitive B | 1996 |
Long-term outcome of panic disorder treatment. A review of the literature.
Topics: Agoraphobia; Combined Modality Therapy; Follow-Up Studies; Humans; Imipramine; Panic Disorder; Psych | 1996 |
Antidepressants in panic disorder.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Drug Administration Schedule; Drug Therapy, | 1997 |
Panic disorder: long-term pharmacotherapy and discontinuation.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Chronic Disease; Controlled Clini | 1998 |
Rational treatment of panic disorder with antidepressants.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Comorbidity; Dose-Response | 1998 |
Imipramine-induced hyperpigmentation: four cases and a review of the literature.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Humans; Hyperpigmentation; Imipramine; M | 1999 |
Clinical efficacy of reboxetine in major depression.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Controlled Clinical Trials as Topic; | 2000 |
83 trials available for imipramine and Panic Disorder
| Article | Year |
|---|---|
Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Comb | 2008 |
Relapse following combined treatment discontinuation in a placebo-controlled trial for panic disorder.
Topics: Adult; Agoraphobia; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Follow-Up Studi | 2008 |
The effect of pharmacotherapist characteristics on treatment outcome in panic disorder.
Topics: Adult; Anti-Anxiety Agents; Bias; Clinical Competence; Cognitive Behavioral Therapy; Combined Modali | 2003 |
Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder.
Topics: Adult; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Double-Blind Method; Fema | 2003 |
Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Double-Blind Method; Drug Administration Sched | 1999 |
Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy.
Topics: Adult; Benzodiazepines; Buspirone; Chi-Square Distribution; Double-Blind Method; Female; Follow-Up S | 2003 |
Sertraline in panic disorder: initial treatment versus switch strategy.
Topics: Adrenergic Uptake Inhibitors; Adult; Cohort Studies; Female; Humans; Imipramine; Male; Middle Aged; | 2003 |
A 15-year follow-up study of patients with panic disorder.
Topics: Activities of Daily Living; Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Sec | 2003 |
Switching from imipramine to sertraline in panic disorder.
Topics: Adult; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; | 2004 |
Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Dose-Response Re | 2005 |
Psychopathology of panic attacks in panic disorder.
Topics: Agoraphobia; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Cognition; Humans; I | 2006 |
A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy.
Topics: Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Combined Modality Therapy; Fatigue; | 2007 |
Cost-efficacy of individual and combined treatments for panic disorder.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognitive Behavioral The | 2007 |
Pattern of placebo response in panic disorder.
Topics: Alprazolam; Follow-Up Studies; Humans; Imipramine; Panic Disorder; Placebo Effect; Time Factors; Tre | 1995 |
Panic disorder with or without concomitant depression 5 years after treatment: a prospective follow-up.
Topics: Adult; Agoraphobia; Combined Modality Therapy; Comorbidity; Depressive Disorder; Doxepin; Female; Fo | 1995 |
Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
Topics: Adult; Agoraphobia; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Drug Adm | 1995 |
Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study.
Topics: Adolescent; Adult; Agoraphobia; Female; Fluoxetine; Humans; Imipramine; Male; Middle Aged; Panic Dis | 1995 |
Dose-response characterization of the antipanic effects of imipramine.
Topics: Dose-Response Relationship, Drug; Humans; Imipramine; Panic Disorder | 1994 |
Three years follow-up of panic disorder patients: a naturalistic study.
Topics: Adult; Alprazolam; Analysis of Variance; Chronic Disease; Female; Follow-Up Studies; Humans; Imipram | 1994 |
A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder.
Topics: Adolescent; Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Desensitization, Psychol | 1994 |
Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo.
Topics: Adult; Aged; Alprazolam; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Humans; Imip | 1994 |
Cognitive behavior therapy for treatment-refractory panic disorder.
Topics: Adult; Alprazolam; Clonazepam; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Fluo | 1994 |
Subtyping of panic disorder by symptom profile.
Topics: Adult; Alprazolam; Colombia; Europe; Female; Humans; Imipramine; Interview, Psychological; Linear Mo | 1993 |
Maintenance drug therapy of panic disorder.
Topics: Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imipramine; | 1993 |
Blood pressure and heart rate response of panic disorder patients receiving imipramine in a dose-response treatment paradigm.
Topics: Adult; Agoraphobia; Analysis of Variance; Blood Pressure; Dose-Response Relationship, Drug; Double-B | 1994 |
Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo.
Topics: Adolescent; Adult; Aged; Alprazolam; Double-Blind Method; Humans; Imipramine; Middle Aged; Panic Dis | 1994 |
A comparison of symptom determinants of patient and clinician global ratings in patients with panic disorder and depression.
Topics: Adult; Aged; Alprazolam; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; | 1993 |
Outcome of panic disorder with or without concomitant depression: A 2-year prospective follow-up study.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Combined Modality Therapy; Comorbidity; Depressive Di | 1993 |
Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo.
Topics: Adult; Aged; Alprazolam; Arousal; Depressive Disorder; Double-Blind Method; Female; Humans; Imiprami | 1993 |
Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.
Topics: Adolescent; Adult; Agoraphobia; Alprazolam; Dose-Response Relationship, Drug; Double-Blind Method; D | 1993 |
Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine.
Topics: Adult; Agoraphobia; Alprazolam; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Me | 1993 |
Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper.
Topics: Adult; Alprazolam; Ambulatory Care; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 1993 |
Changes in appetite and weight during the pharmacological treatment of patients with panic disorder.
Topics: Adult; Agoraphobia; Appetite; Body Weight; Diazepam; Dietary Carbohydrates; Double-Blind Method; Fem | 1993 |
Imipramine treatment of alcoholism with comorbid depression.
Topics: Adult; Affect; Alcohol Drinking; Alcoholism; Comorbidity; Depressive Disorder; Disulfiram; Dose-Resp | 1993 |
A multiple imputation strategy for clinical trials with truncation of patient data.
Topics: Adult; Alprazolam; Ambulatory Care; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Bayes The | 1995 |
Fluctuation of symptoms and social functioning in panic disorder with or without concomitant depression. A 5-year prospective follow-up.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Doxepin; Follow-Up | 1995 |
Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Female; GABA Modulators; gamma-Aminobutyric Aci | 1995 |
Minnesota Multiphasic Personality Inventory correlates of panic disorder with agoraphobia: changes with treatment.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Clomipramine; Female; Humans; Imip | 1995 |
Phenomenology of panic attacks: responsiveness of individual symptoms to imipramine.
Topics: Adult; Antidepressive Agents, Tricyclic; Dose-Response Relationship, Drug; Double-Blind Method; Fema | 1996 |
Long-term follow-up after a drug trial for panic disorder.
Topics: Adolescent; Adult; Aged; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Dose-Res | 1995 |
The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder.
Topics: Adult; Desipramine; Dose-Response Relationship, Drug; Female; Humans; Imipramine; Male; Panic Disord | 1996 |
Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial.
Topics: Alprazolam; Follow-Up Studies; Humans; Imipramine; Panic Disorder; Prognosis; Prospective Studies; Q | 1996 |
A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
Topics: Adult; Agoraphobia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluvoxamine; Huma | 1996 |
Predictors of outcome in panic disorder: a 5-year prospective follow-up study.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Doxepin | 1996 |
Service utilization and expenditures for the treatment of panic disorder.
Topics: Adult; Alprazolam; Ambulatory Care; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Community | 1997 |
Growing placebo response rate: the problem in recent therapeutic trials?
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Double- | 1997 |
Overcoming resistance to exposure in panic disorder with agoraphobia.
Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Defense Mechanisms; Desensitization, | 1997 |
Decline in serum lactate levels over time.
Topics: Administration, Oral; Adult; Antidepressive Agents, Tricyclic; Circadian Rhythm; Cross-Over Studies; | 1994 |
Lactate-induced anxiety after imipramine and diazepam treatment.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Arousal | 1994 |
Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Double-Blind Method; Female; Fluvoxami | 1996 |
Effect of antipanic treatment on response to carbon dioxide.
Topics: Administration, Inhalation; Adult; Antidepressive Agents, Tricyclic; Behavior Therapy; Carbon Dioxid | 1997 |
Pretreatment attrition in a comparative treatment outcome study on panic disorder.
Topics: Adolescent; Adult; Clinical Protocols; Cognitive Behavioral Therapy; Combined Modality Therapy; Fema | 1998 |
Effects of panic disorder treatments on personality disorder characteristics.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Cognitive Behavioral Therapy; Female; Follow-Up Studi | 1998 |
Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorders.
Topics: Adult; Antidepressive Agents, Tricyclic; Brain Chemistry; Female; Functional Laterality; Glucose; Hi | 1998 |
Panic disorder: long-term pharmacotherapy and discontinuation.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Chronic Disease; Controlled Clini | 1998 |
Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Blood Platelets; Down-Regulation; GTP-Binding | 1999 |
Application of a new statistical approach to evaluate a clinical trial with panic disorder patients.
Topics: Adult; Agoraphobia; Clinical Trials as Topic; Desensitization, Psychologic; Female; Humans; Imiprami | 1999 |
Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo.
Topics: Aged; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Dose-Response Relationship, | 1999 |
The use of the Panic and Agoraphobia Scale in a clinical trial.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Combined Modality Therapy; Desensitization, Ps | 1998 |
Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Combine | 2000 |
Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety; Carbon Dioxide; Double-Blind Method; Female; Human | 1997 |
A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants.
Topics: Adult; Aged; Agoraphobia; Antidepressive Agents; Clomipramine; Demography; Female; Humans; Imipramin | 2000 |
The side effects burden of extended imipramine treatment of panic disorder.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Blood Pressure; Female; Heart Rate; Humans; Im | 2000 |
2nd year maintenance and discontinuation of imipramine in panic disorder with agoraphobia.
Topics: Agoraphobia; Antidepressive Agents, Tricyclic; Drug Administration Schedule; Female; Humans; Imipram | 2001 |
Emotion-focused psychotherapy for patients with panic disorder.
Topics: Adult; Agoraphobia; Cognitive Behavioral Therapy; Emotions; Female; Humans; Imipramine; Male; Middle | 2001 |
Respiratory variability in panic disorder.
Topics: Adult; Arousal; Autonomic Nervous System; Carbon Dioxide; Cognitive Behavioral Therapy; Depressive D | 2001 |
Specific side effects of long-term imipramine management of panic disorder.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Agoraphobia; Arousal; Dose-Response Relationship, Dr | 2002 |
Duration of imipramine therapy and relapse in panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Analysis of Variance; Antidepressive Agents, Tricyclic; Chi-Square Distribution; | 2002 |
[Patients with panic disorder: a 5-year follow-up study].
Topics: Adult; Alprazolam; Double-Blind Method; Female; Follow-Up Studies; Humans; Imipramine; Male; Middle | 1992 |
Pretreatment anxiety level as differential predictor in outpatients with panic disorder.
Topics: Adult; Alprazolam; Anxiety; Female; Humans; Imipramine; Male; Outpatients; Panic Disorder; Prognosis | 1992 |
Treatment of panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Imipramine; Male; Panic Disorde | 1992 |
Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial.
Topics: Adult; Clomipramine; Diazepam; Double-Blind Method; Female; Humans; Imipramine; Male; Panic Disorder | 1992 |
Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators.
Topics: Adult; Alprazolam; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Imipramine; Neurops | 1992 |
Imipramine and alprazolam effects on stress test reactivity in panic disorder.
Topics: Adult; Alprazolam; Anxiety; Arrhythmias, Cardiac; Blood Pressure; Carbon Dioxide; Cold Temperature; | 1992 |
Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder.
Topics: Adolescent; Adult; Aged; Alprazolam; Analysis of Variance; Double-Blind Method; Drug Therapy, Combin | 1992 |
Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Blood Pressure; Body Weight; Double-Blind Method; Drug Administration Schedule; | 1992 |
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Alprazolam; Disability Evaluation; Double-Blind | 1992 |
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Alprazolam; Disability Evaluation; Double-Blind | 1992 |
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Alprazolam; Disability Evaluation; Double-Blind | 1992 |
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Alprazolam; Disability Evaluation; Double-Blind | 1992 |
Imipramine-induced jitteriness and decreased serum iron levels.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Double-Blind Method; Female; Humans; Imiprami | 1992 |
Center differences and cross-national invariance in help-seeking for panic disorder. A report from the cross-national collaborative panic study.
Topics: Adult; Alprazolam; Cross-Cultural Comparison; Cross-Sectional Studies; Female; Humans; Imipramine; I | 1992 |
Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia.
Topics: Adult; Agoraphobia; Ambulatory Care; Double-Blind Method; Drug Administration Schedule; Female; Foll | 1992 |
Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?
Topics: Adult; Agoraphobia; Alprazolam; Arousal; Double-Blind Method; Fear; Female; Humans; Imipramine; Male | 1991 |
The changes of thyroid hormone during pharmacological treatment of panic disorder patients.
Topics: Adult; Analysis of Variance; Anxiety; Chi-Square Distribution; Diazepam; Double-Blind Method; Female | 1991 |
The structure of phobias in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Double-Blind Method; Female; Humans; Imipramine; Male; Middle Aged; | 1991 |
47 other studies available for imipramine and Panic Disorder
| Article | Year |
|---|---|
Effects of the adjunctive treatment of antidepressants with opiorphin on a panic-like defensive response in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Drug Th | 2020 |
Low-dose imipramine for treatment of panic disorder during pregnancy: a retrospective chart review.
Topics: Adult; Antidepressive Agents, Tricyclic; Dose-Response Relationship, Drug; Female; Humans; Imipramin | 2014 |
Low-Dose Imipramine for the Treatment of Panic Disorder During Postpartum Period: A Retrospective Analysis of 6 Cases.
Topics: Adult; Antidepressive Agents, Tricyclic; Female; Humans; Imipramine; Panic Disorder; Postpartum Peri | 2016 |
Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale.
Topics: Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Combined Modalit | 2009 |
Chronic dizziness presenting in a patient with panic disorder: response to imipramine.
Topics: Adult; Antidepressive Agents, Tricyclic; Chronic Disease; Dizziness; Female; Humans; Imipramine; Pan | 2009 |
Imipramine on the treatment of chronic dizziness and panic disorder--3 cases report.
Topics: Adult; Antidepressive Agents, Tricyclic; Dizziness; Female; Humans; Imipramine; Panic Disorder; Trea | 2010 |
Imipramine for vestibular dysfunction in panic disorder: a prospective case series.
Topics: Adolescent; Adult; Agoraphobia; Antidepressive Agents, Tricyclic; Chronic Disease; Dizziness; Female | 2011 |
A latent class approach to the external validation of respiratory and non-respiratory panic subtypes.
Topics: Age of Onset; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents; Diagnostic and Statistical Man | 2012 |
Effects of chronic corticosterone and imipramine administration on panic and anxiety-related responses.
Topics: Animals; Antidepressive Agents, Tricyclic; Anxiety; Behavior, Animal; Corticosterone; Escape Reactio | 2011 |
Assessment of anxiolytic and panicolytic effects of dichloromethane fraction from stems of Kielmeyera coriacea.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Behavior, Animal; Clusiacea | 2012 |
Treatment of mitral valve prolapse and panic disorder with metoprolol.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Adult; Humans; Imipramine; Male; Metoprol | 2000 |
Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Health Care Costs; Humans; Imipramine; Panic Disord | 2000 |
Piloerection induced by replacing fluvoxamine with milnacipran.
Topics: Adult; Antidepressive Agents; Cyclopropanes; Female; Fluvoxamine; Humans; Imipramine; Milnacipran; M | 2007 |
Preliminary evidence for cognitive mediation during cognitive-behavioral therapy of panic disorder.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Cognition; Cognitive Behavioral Therapy; Female; Huma | 2007 |
More reliable outcome measures can reduce sample size requirements.
Topics: Alprazolam; Depressive Disorder; Humans; Imipramine; Panic Disorder; Placebos; Psychiatric Status Ra | 1995 |
[Integrated treatment strategies in panic disorder with agoraphobia and depressive disorder].
Topics: Adult; Agoraphobia; Behavior Therapy; Child; Combined Modality Therapy; Depressive Disorder; Dose-Re | 1995 |
Clinical recovery from panic disorder is associated with evidence of changes in cardiovascular regulation.
Topics: Adolescent; Adult; Aged; Arousal; Baroreflex; Blood Pressure; Catecholamines; Cognitive Behavioral T | 1995 |
Effects of treatment with imipramine and clonazepam on an animal model of panic disorder.
Topics: Analysis of Variance; Animals; Bicuculline; Clonazepam; Disease Models, Animal; Double-Blind Method; | 1994 |
[Treatment refractory panic disorder--success of a combined treatment with imipramine, moclobemide and behavior therapy].
Topics: Adult; Agoraphobia; Antidepressive Agents; Behavior Therapy; Benzamides; Combined Modality Therapy; | 1995 |
Mania or panic associated with dexamethasone chemotherapy in adolescents.
Topics: Adolescent; Bipolar Disorder; Dexamethasone; Female; Humans; Imipramine; Lithium; Mental Status Sche | 1994 |
Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets.
Topics: Adult; Anxiety Disorders; Arousal; Blood Platelets; Depressive Disorder; Female; Humans; Hydrocortis | 1994 |
Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients.
Topics: Adult; Alprazolam; Antidepressive Agents, Tricyclic; Desipramine; Drug Therapy, Combination; Female; | 1994 |
Long-term outcome of panic disorder after short-term imipramine and behavioral group treatment: 2.9-year naturalistic follow-up study.
Topics: Adult; Agoraphobia; Behavior Therapy; Combined Modality Therapy; Desensitization, Psychologic; Femal | 1993 |
Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls.
Topics: Adult; Binding Sites; Biological Transport; Blood Platelets; Female; Humans; Imipramine; Male; Panic | 1994 |
Panic disorder masquerading as pre-eclampsia.
Topics: Adult; Diagnosis, Differential; Female; Humans; Imipramine; Panic Disorder; Postpartum Period; Pre-E | 1993 |
Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients.
Topics: Adult; Ambulatory Care; Female; Humans; Imipramine; Male; Panic Disorder; Severity of Illness Index; | 1994 |
A naturalistic 6-year follow-up study of patients with panic disorder.
Topics: Adult; Alcoholism; Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Comorbidity; D | 1996 |
Platelet imipramine binding in patients with posttraumatic stress disorder before and after phenelzine treatment.
Topics: Adult; Agoraphobia; Anxiety Disorders; Binding Sites; Blood Platelets; Depressive Disorder; Humans; | 1996 |
Chronic administration of antipanic drugs alters rat brainstem GABAA receptor subunit mRNA levels.
Topics: Animals; Anti-Anxiety Agents; Brain Stem; Buspirone; GABA Agonists; GABA-A Receptor Agonists; Imipra | 1996 |
Panic attacks, complex partial seizures, and multiple meningiomas.
Topics: Adult; Antidepressive Agents, Tricyclic; Cerebral Ventricles; Epilepsy, Complex Partial; Female; Hip | 1994 |
The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
Topics: Agoraphobia; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Arousal; Dose-Response Relations | 1997 |
Effect of imipramine treatments on the 5-HT1A-receptor-mediated inhibition of panic-like behaviours in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antidepressive Agents, Tricyc | 1997 |
Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia.
Topics: Adolescent; Adult; Aged; Agoraphobia; Antidepressive Agents, Tricyclic; Female; Follow-Up Studies; H | 1998 |
Experimental procedures and the placebo response.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Humans; Imipramine; Panic Disorde | 1998 |
[Coincidence of schizophrenia and panic disorder].
Topics: Agoraphobia; Cognitive Behavioral Therapy; Combined Modality Therapy; Dibenzothiepins; Female; Human | 1999 |
Panic disorder--it's real and it's treatable.
Topics: Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Humans; Imipramine; Panic Disorder | 2000 |
MDMA ("ecstasy") and panic disorder: induction by a single dose.
Topics: 3,4-Methylenedioxyamphetamine; Administration, Oral; Adult; Alprazolam; Anxiety Disorders; Arousal; | 1992 |
[Treatment of patients with panic disorder and an elevated urinary excretion of MHPG using imipramine or clonazepam].
Topics: Adult; Anxiety Disorders; Clonazepam; Depression; Female; Humans; Imipramine; Lactates; Lactic Acid; | 1992 |
Insight and illusion.
Topics: Depressive Disorder; Factor Analysis, Statistical; Humans; Imipramine; Panic Disorder; Personality I | 1992 |
Effect of imipramine treatment on heart rate variability measures.
Topics: Adult; Agoraphobia; Arousal; Blood Pressure; Depressive Disorder; Electrocardiography; Female; Heart | 1992 |
A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.
Topics: Agoraphobia; Alprazolam; Female; Humans; Imipramine; Male; Panic Disorder; Psychiatric Status Rating | 1992 |
Panic disorder and anger attacks.
Topics: Anger; Child; Dose-Response Relationship, Drug; Female; Humans; Imipramine; Panic Disorder | 1992 |
Tricyclic antidepressant-induced seizures and plasma drug concentration.
Topics: Adult; Ambulatory Care; Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder; Desipr | 1992 |
Painful ejaculation associated with antidepressants in four patients.
Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Depressive Disorder; Ejaculation; Humans; Imi | 1991 |
Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients.
Topics: Adult; Agoraphobia; Clomipramine; Dexamethasone; Diagnosis, Differential; Female; Humans; Hydrocorti | 1991 |
Follow-up study of patients with panic disorder.
Topics: Alprazolam; Antidepressive Agents, Tricyclic; Behavior Therapy; Combined Modality Therapy; Follow-Up | 1991 |
Surreptitious drug use by panic disorder patients.
Topics: Alprazolam; Clinical Trials as Topic; Humans; Imipramine; Panic Disorder; Placebos; Self Medication | 1991 |